YU45102A - Novi kristalni oblik leflunomida i novi postupci za njegovo dobijanje - Google Patents
Novi kristalni oblik leflunomida i novi postupci za njegovo dobijanjeInfo
- Publication number
- YU45102A YU45102A YU45102A YUP45102A YU45102A YU 45102 A YU45102 A YU 45102A YU 45102 A YU45102 A YU 45102A YU P45102 A YUP45102 A YU P45102A YU 45102 A YU45102 A YU 45102A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- leflunomide
- making
- crystalline form
- new crystalline
- novel processes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
Abstract
Opisan je novi Oblik III leflunomida, kao i postupak njegovog dobijanja. Predmetni pronalazak takođe obezbeđuje ekonomični postupak dobijanja Oblika II leflunomida i postupak dobijanja Oblika I iz Oblika III leflunomida. Takođe su opisani i farmaceutski preparati, oblici za doziranje koji sadrže novi oblik i postupci njihove primene u lečenju reumatoidnog artritisa.[New leflunomide Form III is disclosed, along with processes for preparing it. The present invention also provides an economic process for preparing leflunomide Form II and a process for preparing leflunomide Form I from leflunomide Form III. Pharmaceutical compositions and dosage forms containing the new form and methods of using them for the treatment of rheumatoid arthritis are also disclosed.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17122899P | 1999-12-16 | 1999-12-16 | |
US17123799P | 1999-12-16 | 1999-12-16 | |
US18264700P | 2000-02-15 | 2000-02-15 | |
US20241600P | 2000-05-08 | 2000-05-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
YU45102A true YU45102A (sh) | 2006-01-16 |
Family
ID=27496942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU45102A YU45102A (sh) | 1999-12-16 | 2000-12-14 | Novi kristalni oblik leflunomida i novi postupci za njegovo dobijanje |
Country Status (15)
Country | Link |
---|---|
US (3) | US6610718B2 (sh) |
EP (1) | EP1242077A4 (sh) |
JP (1) | JP2003517011A (sh) |
KR (1) | KR20020067545A (sh) |
CN (1) | CN1411373A (sh) |
AU (1) | AU779931B2 (sh) |
CA (1) | CA2397601A1 (sh) |
CZ (1) | CZ20022000A3 (sh) |
HR (2) | HRP20020521A2 (sh) |
HU (1) | HUP0204069A3 (sh) |
IL (1) | IL149792A0 (sh) |
PL (1) | PL356243A1 (sh) |
SK (1) | SK8332002A3 (sh) |
WO (1) | WO2001043742A1 (sh) |
YU (1) | YU45102A (sh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE196764T1 (de) * | 1997-08-08 | 2000-10-15 | Aventis Pharma Gmbh | Kristallform von 5-methylisoxazol-4-carbonsäure- (4-trifluormethyl)-anilid |
PL356243A1 (en) * | 1999-12-16 | 2004-06-28 | Teva Pharmaceuticals Industries Ltd. | Novel processes for making- and a new crystalline form of- leflunomide |
WO2001051089A1 (de) * | 2000-01-13 | 2001-07-19 | Merck Patent Gmbh | Pharmazeutische zubereitungen enthaltend 2-pyrrolidon als lösungsvermittler |
SK12992002A3 (sk) * | 2000-02-15 | 2003-05-02 | Teva Pharmaceutical Industries Ltd. | Spôsob syntézy leflunomidu |
US20050158371A1 (en) * | 2002-02-12 | 2005-07-21 | Sumitomo Pharmaceuticals Co., Ltd. | Novel external agent |
WO2006103506A1 (en) * | 2005-03-31 | 2006-10-05 | Ranbaxy Laboratories Limited | Sertraline-containing pharmaceutical compositions and a process for preparation thereof |
CN101563082A (zh) * | 2006-09-05 | 2009-10-21 | 窦德献 | 治疗免疫介导性皮肤病的组合物和方法 |
CN101143834B (zh) * | 2006-09-15 | 2010-09-08 | 欣凯医药化工中间体(上海)有限公司 | N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法 |
CA2694242C (en) | 2007-06-29 | 2013-10-01 | Generics [Uk] Limited | Process for introduction of hydroxyethoxy side chain in bosentan |
WO2009053748A2 (en) | 2007-10-24 | 2009-04-30 | Generics [Uk] Limited | Novel crystalline forms |
ES2650247T3 (es) | 2008-02-08 | 2018-01-17 | Generics [Uk] Limited | Procedimiento de preparación del bosentán |
AU2009321375A1 (en) | 2008-11-03 | 2010-06-03 | Generics [Uk] Limited | HPLC method for the analysis of bosentan and related substances and use of these substances as reference standards and markers |
CN101817797B (zh) * | 2009-02-26 | 2013-04-10 | 江苏亚邦爱普森药业有限公司 | 高纯度3-甲基-n-[4-(三氟甲基)苯基]-4-异噁唑甲酰胺的合成方法 |
RU2021125455A (ru) | 2013-11-15 | 2021-10-05 | Экебиа Терапьютикс, Инк. | Твердые формы { [5-(3-хлорфенил)-3-гидроксипиридин-2-карбонил]амино} уксусной кислоты, их композиции и применения |
US11801232B2 (en) * | 2019-11-27 | 2023-10-31 | Yale University | Targeting of ARID1A-deficient cancers by inhibiting de novo pyrimidine synthesis pathway |
CN112898215B (zh) * | 2021-02-04 | 2022-11-08 | 美罗药业股份有限公司 | 一种来氟米特晶型i的制备方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2854439A1 (de) * | 1978-12-16 | 1980-07-03 | Hoechst Ag | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
US5268382A (en) * | 1985-09-27 | 1993-12-07 | Hoechst Aktiengesellschaft | Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus |
DE3534440A1 (de) * | 1985-09-27 | 1987-04-02 | Hoechst Ag | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes |
GB8619432D0 (en) * | 1986-08-08 | 1986-09-17 | Lilly Industries Ltd | Pharmaceutical compounds |
DE59010701D1 (de) * | 1990-05-18 | 1997-05-22 | Hoechst Ag | Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung |
US5610173A (en) * | 1994-01-07 | 1997-03-11 | Sugen, Inc. | Formulations for lipophilic compounds |
US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
DE19610955A1 (de) * | 1996-03-20 | 1997-09-25 | Hoechst Ag | Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid |
GB9624038D0 (en) * | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
DE19711800A1 (de) * | 1997-03-21 | 1998-09-24 | Hoechst Ag | Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung |
ATE196764T1 (de) * | 1997-08-08 | 2000-10-15 | Aventis Pharma Gmbh | Kristallform von 5-methylisoxazol-4-carbonsäure- (4-trifluormethyl)-anilid |
EP0933633A1 (en) * | 1997-12-11 | 1999-08-04 | Hoechst Marion Roussel Deutschland GmbH | Process for obtaining L-dihydroorotic acid and use thereof |
US7691890B2 (en) * | 1998-03-11 | 2010-04-06 | James W. Williams | Anti-viral uses of leflunomide products |
US6303652B1 (en) * | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
DE19908527C2 (de) * | 1999-02-26 | 2001-08-30 | Aventis Pharma Gmbh | Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid |
AU780973B2 (en) * | 1999-06-25 | 2005-04-28 | Vertex Pharmaceuticals Incorporated | Prodrugs of carbamate inhibitors of IMPDH |
PL356243A1 (en) * | 1999-12-16 | 2004-06-28 | Teva Pharmaceuticals Industries Ltd. | Novel processes for making- and a new crystalline form of- leflunomide |
SK12992002A3 (sk) * | 2000-02-15 | 2003-05-02 | Teva Pharmaceutical Industries Ltd. | Spôsob syntézy leflunomidu |
AU2001251011A1 (en) * | 2000-03-27 | 2001-10-08 | The General Hospital Corporation | Treatments for immune-mediated ear disorders |
US20020077485A1 (en) * | 2000-08-14 | 2002-06-20 | Ilya Avrutov | Micronized leflunomide |
ATE423092T1 (de) * | 2000-08-24 | 2009-03-15 | Univ Tennessee Res Foundation | Selektive modulatoren des androgenrezeptors und methoden zu deren verwendung |
JP4212278B2 (ja) * | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
US20040229849A1 (en) * | 2002-09-24 | 2004-11-18 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
JP2007502281A (ja) * | 2003-08-13 | 2007-02-08 | メドトロニック・インコーポレーテッド | 混和性ポリマー配合物を含む活性剤放出系、医療機器、及び方法 |
WO2005018697A2 (en) * | 2003-08-13 | 2005-03-03 | Medtronic, Inc. | Active agent delivery systems, including a single layer of a miscible polymer blend, medical devices, and methods |
US20050053600A1 (en) * | 2003-09-09 | 2005-03-10 | Lane Thomas E. | Methods for treating rheumatoid arthritis |
-
2000
- 2000-12-14 PL PL00356243A patent/PL356243A1/xx not_active Application Discontinuation
- 2000-12-14 SK SK833-2002A patent/SK8332002A3/sk unknown
- 2000-12-14 KR KR1020027007575A patent/KR20020067545A/ko not_active Application Discontinuation
- 2000-12-14 WO PCT/US2000/033866 patent/WO2001043742A1/en not_active Application Discontinuation
- 2000-12-14 HU HU0204069A patent/HUP0204069A3/hu unknown
- 2000-12-14 EP EP00989253A patent/EP1242077A4/en not_active Withdrawn
- 2000-12-14 CN CN00817283A patent/CN1411373A/zh active Pending
- 2000-12-14 CA CA002397601A patent/CA2397601A1/en not_active Abandoned
- 2000-12-14 AU AU25788/01A patent/AU779931B2/en not_active Ceased
- 2000-12-14 CZ CZ20022000A patent/CZ20022000A3/cs unknown
- 2000-12-14 US US09/736,727 patent/US6610718B2/en not_active Expired - Fee Related
- 2000-12-14 JP JP2001544880A patent/JP2003517011A/ja active Pending
- 2000-12-14 IL IL14979200A patent/IL149792A0/xx unknown
- 2000-12-14 YU YU45102A patent/YU45102A/sh unknown
-
2002
- 2002-06-14 HR HR20020521A patent/HRP20020521A2/hr not_active Application Discontinuation
-
2003
- 2003-04-08 US US10/410,493 patent/US6806373B2/en not_active Expired - Fee Related
-
2004
- 2004-07-22 US US10/897,778 patent/US20050004191A1/en not_active Abandoned
-
2005
- 2005-02-23 HR HR20050176A patent/HRP20050176A2/xx not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1242077A1 (en) | 2002-09-25 |
US20050004191A1 (en) | 2005-01-06 |
US20010031878A1 (en) | 2001-10-18 |
US6610718B2 (en) | 2003-08-26 |
AU779931B2 (en) | 2005-02-17 |
PL356243A1 (en) | 2004-06-28 |
KR20020067545A (ko) | 2002-08-22 |
CA2397601A1 (en) | 2001-06-21 |
HUP0204069A2 (hu) | 2003-04-28 |
HRP20020521A2 (en) | 2004-08-31 |
CN1411373A (zh) | 2003-04-16 |
SK8332002A3 (en) | 2003-04-01 |
WO2001043742A1 (en) | 2001-06-21 |
HUP0204069A3 (en) | 2005-01-28 |
IL149792A0 (en) | 2002-11-10 |
US6806373B2 (en) | 2004-10-19 |
AU2578801A (en) | 2001-06-25 |
EP1242077A4 (en) | 2006-01-04 |
US20030203952A1 (en) | 2003-10-30 |
CZ20022000A3 (cs) | 2003-02-12 |
JP2003517011A (ja) | 2003-05-20 |
HRP20050176A2 (en) | 2005-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU45102A (sh) | Novi kristalni oblik leflunomida i novi postupci za njegovo dobijanje | |
PL345215A1 (en) | Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same | |
HK1067120A1 (en) | Glutaminyl based dpiv inhibitors | |
IL132763A0 (en) | Novel compounds | |
PL340836A1 (en) | Novel compounds | |
GR3030342T3 (en) | Cyclobutane derivatives as inhibitors of squalene synthetase and protein farnesyltransferase. | |
MX9805253A (es) | Antagonistas del receptor de vitronectina. | |
MXPA02012795A (es) | Carvedilol. | |
PL293795A1 (en) | Method of obtaining cyclic urea derivatives | |
HU9300685D0 (en) | Method for producing crystallic momethazone-furoate-monohydrate and pharmaceutical preparatives containing it | |
GB0016040D0 (en) | Novel process for preparing crystalline particles | |
PT1237575E (pt) | Antagonista de tnf-alfa e antagonista de lfa-1 para tratar a artrite reumatóide | |
BG105009A (en) | Method for producing 4-carboxyamino-2-substituted 1,2,3,4-tetrahydroquinoline | |
UA66865C2 (uk) | Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти) | |
GB0015981D0 (en) | Novel process for preparing crystalline particles | |
HU9601113D0 (en) | Delta16 unsaturated c17 heterocyclic steroids useful as steroid c17-20 lyase inhibitors, pharmaceutical compositions containing them and process for their production | |
ES8609312A1 (es) | Procedimiento para la preparacion de silibinina exenta de isosilibina | |
HRP20010969B1 (en) | Novel piperazinylalkylthiopyrimidine derivatives, | |
IL80853A (en) | Process for the production of podophyllotoxin and related compounds,certain intermediates therefor and their preparation | |
YU12000A (sh) | Supstituisani 1,2,3,4,5,6-heksahidro-2,6-metano-3-benzazocin -10-oli, postupak za njihovo pripremanje i njihova primena kao lekova | |
UA66792C2 (uk) | Спосіб отримання 2-арил-3-арил-5-галогенпіридинів, що використовуються як інгібітори сох-2 (варіанти) | |
IL146811A0 (en) | Novel method for preparing benzoperhydroisoindole compounds | |
GB9909229D0 (en) | Enantiomers of mercapto lactones and processes for their synthesis | |
MY127328A (en) | 5-amino-1-pentene-3-ol substituted derivatives | |
BG108151A (en) | Caloporoside derivatives, methods for the production thereof and their use |